 SUZHOU, China and PALO ALTO, Calif., March 31, 2021 PRNewswire -- Gracell Biotechnologies Inc. NASDAQ:GRCLGracell, a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the company has entered into a Manufacturing Service Agreement MSA with Lonza SIX:LONN for clinical manufacturing of Gracells FasTCAR-enabled CAR-T cell product candidates in the U.S. Gracell is advancing its innovative CAR-T pipeline globally for difficult-to-treat cancers, including its lead program for GC012F, a BCMACD19 dual-targeting CAR-T therapy for multiple myeloma. 